Cost-effectiveness analysis of PD-L1 testing associated with pembrolizumab for first-line treatment of advanced non-small cell lung cancer in China
International Journal of Clinical Pharmacy · 2025
DOI: 10.1007/s11096-025-01865-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Pharmacy, 2025. Verfasst von Yao Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Health Policy and Technology Evaluation, Peking University Health Science Center, Beijing, 100191, China. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Carcinoma, Non-Small-Cell Lung, Antibodies, Monoclonal, Humanized, Lung Neoplasms. Die Arbeit nennt 39 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Lung cancer is the leading cause of cancer-related deaths in China, and pembrolizumab shows differential efficacy in advanced non-small cell lung cancer (NSCLC) with different PD-L1 expression levels. AIM: To assess the cost-effectiveness of PD-L1 testing associated with pembrolizumab for first-line treatment of NSCLC from the perspective of Chinese healthcare system. METHOD: Over a lifetime horizon, a three-state partitioned survival model was developed to assess the cost-effectiveness of PD-L1 testing and no PD-L1 testing. In the PD-L1 testing group, patients were stratified by PD-L1 tumor proportion score ≥ 50%, 1-49%, or < 1% and received pembrolizumab monotherapy, pembrolizumab plus chemotherapy, or chemotherapy alone, respectively. In the non-PD-L1 testing group, all patients received pembrolizumab plus chemotherapy. Model inputs were obtained from published literature and a healthcare price database, and clinical outcomes from two randomized clinical trials were used. The net monetary benefit (NMB) was estimated for the PD-L1 testing group versus the non-PD-L1 testing group. Deterministic and probabilistic sensitivity analyses, and scenario analyses were conducted to assess robustness of results. RESULTS: Using PD-L1 testing to guide treatment led to cost savings of $49,392.7 and a reduction in quality-adjusted life years (QALYs) of 0.234, resulting in a positive NMB of $46,421.7 at a willingness-to-pay (WTP) threshold of $12,680.8/QALY (GDP per capita in China, 2023). Findings were robust across sensitivity and scenario analyses. CONCLUSION: Using PD-L1 testing to guide first-line pembrolizumab treatment in patients with advanced NSCLC is a cost-effective strategy at a WTP threshold of $12,680.8/QALY for China.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Health Policy and Technology Evaluation, Peking University Health Science Center, Beijing, 100191, China.
- Center for Health Policy and Technology Evaluation, Peking University Health Science Center, Beijing, 100191, China. taolibo@hsc.pku.edu.cn.
- Department of Health Policy and Management, School of Public Health, Peking University, Beijing, 100191, China. taolibo@hsc.pku.edu.cn.
Zitieren
APA
Wu, Y., Tao, L., Liu, C., Wang, F., & Sun, S. (2025). Cost-effectiveness analysis of PD-L1 testing associated with pembrolizumab for first-line treatment of advanced non-small cell lung cancer in China. International Journal of Clinical Pharmacy. https://doi.org/10.1007/s11096-025-01865-8
Vancouver
Wu Y, Tao L, Liu C, Wang F, Sun S. Cost-effectiveness analysis of PD-L1 testing associated with pembrolizumab for first-line treatment of advanced non-small cell lung cancer in China. International Journal of Clinical Pharmacy. 2025. doi:10.1007/s11096-025-01865-8
BibTeX
@article{Wu2025,
author = {Wu, Yao and Tao, Libo and Liu, Chang and Wang, Fangxu and Sun, Shuang},
title = {Cost-effectiveness analysis of PD-L1 testing associated with pembrolizumab for first-line treatment of advanced non-small cell lung cancer in China},
journal = {International Journal of Clinical Pharmacy},
year = {2025},
doi = {10.1007/s11096-025-01865-8}
}
EUVIMED